Stiff Person Spectrum Disorder — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Understanding stiff-person syndrome: Epidemiological trends, diagnostic challenges, and treatment advances.
Riveros Daniela et al. — Journal of neuroimmunology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41793840/
- 2.
Case report of stiff - person syndrome and literature review.
Zhang Qiongfang et al. — IBRO neuroscience reports (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41583856/
- 3.
CAR T cell therapy: Autoimmune neurological uses and neurotoxicities.
Friedman Alec R et al. — Best practice & research. Clinical rheumatology (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41934064/
- 4.
Aggravation of stiff-person syndrome with ophthalmoplegia after tandospirone initiation: a case report
Kaiqi Yang et al. — Frontiers in Immunology (2 April 2026)
https://doi.org/10.3389/fimmu.2026.1749793
- 5.
Stiff-person syndrome with concurrent Graves disease: a rare autoimmune overlap.
Rayan Melanie Natasha et al. — JCEM case reports (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41884087/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Stiff Person Spectrum Disorder
Stiff Person Spectrum Disorder is a rare autoimmune neurological condition causing progressive muscle rigidity, painful spasms, and heightened sensitivity to stimuli. It is associated with antibodies against glutamic acid decarboxylase (GAD65) in the majority of cases. Misdiagnosis is common due to its unusual presentation. Treatment includes diazepam, baclofen, and immunotherapy.
Most Recent Research
Stiff-person syndrome spectrum disorders (SPSD) comprise a group of rare neuroimmunological conditions characterized by fluctuating muscle stiffness, painful spasms, gait disturbance, and hypersensitivity triggers. Emerging phenotypes, including posterior fossa dysfunction, highlight the heterogeneity of the spectrum. Although historically described as a "one-in-a-million" disorder, recent epidemiologic data suggest that SPSD is more common than previously recognized. Currently, consensus diagnostic criteria do not exist; however, proposed criteria emphasize key clinical findings, high titers of recognized antibodies and electrophysiology findings that help support a diagnosis. The goal of this review is to provide an overview of SPSD epidemiology with emphasis on prevalence studies, emerging diagnostic criteria and overview of the multimodal treatment approach integrating pharmacological symptomatic therapies, immunotherapy, and non-pharmacologic interventions.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.